Research ArticleArticle
Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset
Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird, Hedley Griffiths, Lynden Roberts, Kathleen Tymms and Geoff Littlejohn
The Journal of Rheumatology December 2019, jrheum.190535; DOI: https://doi.org/10.3899/jrheum.190535
Peter Youssef
From the Royal Prince Alfred Hospital, Camperdown; University of Sydney, Sydney; Roche Products Pty Ltd., Sydney; OzBiostat Pty Ltd., Sydney; University of New South Wales, Sydney; Barwon Rheumatology Service, Geelong; Monash Rheumatology, Clayton; Canberra Rheumatology, Canberra; Monash University, Clayton, Australia. This study was supported by Roche Products Pty Ltd. (Australia). B.M. is an employee of Roche Products Pty Ltd. and reports stock ownership at Roche. P.B. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study. M.T. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. P. Youssef, MD, Professor, Royal Prince Alfred Hospital, and University of Sydney; B. Marcal, BPharm, Roche Products Pty Ltd.; P. Button, MSc, OzBiostat Pty Ltd.; M. Truman, MSc, OzBiostat Pty Ltd.; P. Bird, MD, PhD, Grad Dip MRI, University of New South Wales; H. Griffiths, MD, Barwon Rheumatology Service; L. Roberts, MD, PhD, Associate Professor, Monash Rheumatology; K. Tymms, MD, Associate Professor, Canberra Rheumatology; G. Littlejohn, MD, Professor, Monash University. Address correspondence to Prof. P. Youssef, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. E-mail: pyoussef@med. usyd.edu.au. Accepted for publication November 20, 2019.
Bruno Marcal
From the Royal Prince Alfred Hospital, Camperdown; University of Sydney, Sydney; Roche Products Pty Ltd., Sydney; OzBiostat Pty Ltd., Sydney; University of New South Wales, Sydney; Barwon Rheumatology Service, Geelong; Monash Rheumatology, Clayton; Canberra Rheumatology, Canberra; Monash University, Clayton, Australia. This study was supported by Roche Products Pty Ltd. (Australia). B.M. is an employee of Roche Products Pty Ltd. and reports stock ownership at Roche. P.B. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study. M.T. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. P. Youssef, MD, Professor, Royal Prince Alfred Hospital, and University of Sydney; B. Marcal, BPharm, Roche Products Pty Ltd.; P. Button, MSc, OzBiostat Pty Ltd.; M. Truman, MSc, OzBiostat Pty Ltd.; P. Bird, MD, PhD, Grad Dip MRI, University of New South Wales; H. Griffiths, MD, Barwon Rheumatology Service; L. Roberts, MD, PhD, Associate Professor, Monash Rheumatology; K. Tymms, MD, Associate Professor, Canberra Rheumatology; G. Littlejohn, MD, Professor, Monash University. Address correspondence to Prof. P. Youssef, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. E-mail: pyoussef@med. usyd.edu.au. Accepted for publication November 20, 2019.
Peter Button
From the Royal Prince Alfred Hospital, Camperdown; University of Sydney, Sydney; Roche Products Pty Ltd., Sydney; OzBiostat Pty Ltd., Sydney; University of New South Wales, Sydney; Barwon Rheumatology Service, Geelong; Monash Rheumatology, Clayton; Canberra Rheumatology, Canberra; Monash University, Clayton, Australia. This study was supported by Roche Products Pty Ltd. (Australia). B.M. is an employee of Roche Products Pty Ltd. and reports stock ownership at Roche. P.B. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study. M.T. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. P. Youssef, MD, Professor, Royal Prince Alfred Hospital, and University of Sydney; B. Marcal, BPharm, Roche Products Pty Ltd.; P. Button, MSc, OzBiostat Pty Ltd.; M. Truman, MSc, OzBiostat Pty Ltd.; P. Bird, MD, PhD, Grad Dip MRI, University of New South Wales; H. Griffiths, MD, Barwon Rheumatology Service; L. Roberts, MD, PhD, Associate Professor, Monash Rheumatology; K. Tymms, MD, Associate Professor, Canberra Rheumatology; G. Littlejohn, MD, Professor, Monash University. Address correspondence to Prof. P. Youssef, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. E-mail: pyoussef@med. usyd.edu.au. Accepted for publication November 20, 2019.
Matt Truman
From the Royal Prince Alfred Hospital, Camperdown; University of Sydney, Sydney; Roche Products Pty Ltd., Sydney; OzBiostat Pty Ltd., Sydney; University of New South Wales, Sydney; Barwon Rheumatology Service, Geelong; Monash Rheumatology, Clayton; Canberra Rheumatology, Canberra; Monash University, Clayton, Australia. This study was supported by Roche Products Pty Ltd. (Australia). B.M. is an employee of Roche Products Pty Ltd. and reports stock ownership at Roche. P.B. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study. M.T. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. P. Youssef, MD, Professor, Royal Prince Alfred Hospital, and University of Sydney; B. Marcal, BPharm, Roche Products Pty Ltd.; P. Button, MSc, OzBiostat Pty Ltd.; M. Truman, MSc, OzBiostat Pty Ltd.; P. Bird, MD, PhD, Grad Dip MRI, University of New South Wales; H. Griffiths, MD, Barwon Rheumatology Service; L. Roberts, MD, PhD, Associate Professor, Monash Rheumatology; K. Tymms, MD, Associate Professor, Canberra Rheumatology; G. Littlejohn, MD, Professor, Monash University. Address correspondence to Prof. P. Youssef, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. E-mail: pyoussef@med. usyd.edu.au. Accepted for publication November 20, 2019.
Paul Bird
From the Royal Prince Alfred Hospital, Camperdown; University of Sydney, Sydney; Roche Products Pty Ltd., Sydney; OzBiostat Pty Ltd., Sydney; University of New South Wales, Sydney; Barwon Rheumatology Service, Geelong; Monash Rheumatology, Clayton; Canberra Rheumatology, Canberra; Monash University, Clayton, Australia. This study was supported by Roche Products Pty Ltd. (Australia). B.M. is an employee of Roche Products Pty Ltd. and reports stock ownership at Roche. P.B. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study. M.T. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. P. Youssef, MD, Professor, Royal Prince Alfred Hospital, and University of Sydney; B. Marcal, BPharm, Roche Products Pty Ltd.; P. Button, MSc, OzBiostat Pty Ltd.; M. Truman, MSc, OzBiostat Pty Ltd.; P. Bird, MD, PhD, Grad Dip MRI, University of New South Wales; H. Griffiths, MD, Barwon Rheumatology Service; L. Roberts, MD, PhD, Associate Professor, Monash Rheumatology; K. Tymms, MD, Associate Professor, Canberra Rheumatology; G. Littlejohn, MD, Professor, Monash University. Address correspondence to Prof. P. Youssef, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. E-mail: pyoussef@med. usyd.edu.au. Accepted for publication November 20, 2019.
Hedley Griffiths
From the Royal Prince Alfred Hospital, Camperdown; University of Sydney, Sydney; Roche Products Pty Ltd., Sydney; OzBiostat Pty Ltd., Sydney; University of New South Wales, Sydney; Barwon Rheumatology Service, Geelong; Monash Rheumatology, Clayton; Canberra Rheumatology, Canberra; Monash University, Clayton, Australia. This study was supported by Roche Products Pty Ltd. (Australia). B.M. is an employee of Roche Products Pty Ltd. and reports stock ownership at Roche. P.B. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study. M.T. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. P. Youssef, MD, Professor, Royal Prince Alfred Hospital, and University of Sydney; B. Marcal, BPharm, Roche Products Pty Ltd.; P. Button, MSc, OzBiostat Pty Ltd.; M. Truman, MSc, OzBiostat Pty Ltd.; P. Bird, MD, PhD, Grad Dip MRI, University of New South Wales; H. Griffiths, MD, Barwon Rheumatology Service; L. Roberts, MD, PhD, Associate Professor, Monash Rheumatology; K. Tymms, MD, Associate Professor, Canberra Rheumatology; G. Littlejohn, MD, Professor, Monash University. Address correspondence to Prof. P. Youssef, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. E-mail: pyoussef@med. usyd.edu.au. Accepted for publication November 20, 2019.
Lynden Roberts
From the Royal Prince Alfred Hospital, Camperdown; University of Sydney, Sydney; Roche Products Pty Ltd., Sydney; OzBiostat Pty Ltd., Sydney; University of New South Wales, Sydney; Barwon Rheumatology Service, Geelong; Monash Rheumatology, Clayton; Canberra Rheumatology, Canberra; Monash University, Clayton, Australia. This study was supported by Roche Products Pty Ltd. (Australia). B.M. is an employee of Roche Products Pty Ltd. and reports stock ownership at Roche. P.B. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study. M.T. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. P. Youssef, MD, Professor, Royal Prince Alfred Hospital, and University of Sydney; B. Marcal, BPharm, Roche Products Pty Ltd.; P. Button, MSc, OzBiostat Pty Ltd.; M. Truman, MSc, OzBiostat Pty Ltd.; P. Bird, MD, PhD, Grad Dip MRI, University of New South Wales; H. Griffiths, MD, Barwon Rheumatology Service; L. Roberts, MD, PhD, Associate Professor, Monash Rheumatology; K. Tymms, MD, Associate Professor, Canberra Rheumatology; G. Littlejohn, MD, Professor, Monash University. Address correspondence to Prof. P. Youssef, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. E-mail: pyoussef@med. usyd.edu.au. Accepted for publication November 20, 2019.
Kathleen Tymms
From the Royal Prince Alfred Hospital, Camperdown; University of Sydney, Sydney; Roche Products Pty Ltd., Sydney; OzBiostat Pty Ltd., Sydney; University of New South Wales, Sydney; Barwon Rheumatology Service, Geelong; Monash Rheumatology, Clayton; Canberra Rheumatology, Canberra; Monash University, Clayton, Australia. This study was supported by Roche Products Pty Ltd. (Australia). B.M. is an employee of Roche Products Pty Ltd. and reports stock ownership at Roche. P.B. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study. M.T. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. P. Youssef, MD, Professor, Royal Prince Alfred Hospital, and University of Sydney; B. Marcal, BPharm, Roche Products Pty Ltd.; P. Button, MSc, OzBiostat Pty Ltd.; M. Truman, MSc, OzBiostat Pty Ltd.; P. Bird, MD, PhD, Grad Dip MRI, University of New South Wales; H. Griffiths, MD, Barwon Rheumatology Service; L. Roberts, MD, PhD, Associate Professor, Monash Rheumatology; K. Tymms, MD, Associate Professor, Canberra Rheumatology; G. Littlejohn, MD, Professor, Monash University. Address correspondence to Prof. P. Youssef, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. E-mail: pyoussef@med. usyd.edu.au. Accepted for publication November 20, 2019.
Geoff Littlejohn
From the Royal Prince Alfred Hospital, Camperdown; University of Sydney, Sydney; Roche Products Pty Ltd., Sydney; OzBiostat Pty Ltd., Sydney; University of New South Wales, Sydney; Barwon Rheumatology Service, Geelong; Monash Rheumatology, Clayton; Canberra Rheumatology, Canberra; Monash University, Clayton, Australia. This study was supported by Roche Products Pty Ltd. (Australia). B.M. is an employee of Roche Products Pty Ltd. and reports stock ownership at Roche. P.B. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study. M.T. was an employee of Roche Products Pty Ltd. until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. P. Youssef, MD, Professor, Royal Prince Alfred Hospital, and University of Sydney; B. Marcal, BPharm, Roche Products Pty Ltd.; P. Button, MSc, OzBiostat Pty Ltd.; M. Truman, MSc, OzBiostat Pty Ltd.; P. Bird, MD, PhD, Grad Dip MRI, University of New South Wales; H. Griffiths, MD, Barwon Rheumatology Service; L. Roberts, MD, PhD, Associate Professor, Monash Rheumatology; K. Tymms, MD, Associate Professor, Canberra Rheumatology; G. Littlejohn, MD, Professor, Monash University. Address correspondence to Prof. P. Youssef, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia. E-mail: pyoussef@med. usyd.edu.au. Accepted for publication November 20, 2019.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset
Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird, Hedley Griffiths, Lynden Roberts, Kathleen Tymms, Geoff Littlejohn
The Journal of Rheumatology Dec 2019, jrheum.190535; DOI: 10.3899/jrheum.190535
Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset
Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird, Hedley Griffiths, Lynden Roberts, Kathleen Tymms, Geoff Littlejohn
The Journal of Rheumatology Dec 2019, jrheum.190535; DOI: 10.3899/jrheum.190535